Capula Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capula Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,770	Closed	-$441K	–	824
2022 Q4	$441K	Buy	+2,770	New	+$406K	0.01%	613
2021 Q4	–	Sell	-2,140	Closed	-$279K	–	482
2021 Q3	$279K	Buy	+2,140	New	+$323K	﹤0.01%	718

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Capula Management's JAZZ Position: Q1 2023 in Review

Capula Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 2,770 shares — an estimated $441K sold.

Capula Management first reported a position in JAZZ in Q3 2021 and held it in 2 quarters. The position peaked at $441K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Capula Management reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Capula Management sold 2,770 Jazz Pharmaceuticals shares in Q1 2023, an estimated $441K.
Capula Management first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 2 quarters.
Capula Management's Jazz Pharmaceuticals position peaked at $441K in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Capula Management's 13F filing for Q1 2023, filed 10 May 2023.